OverviewSuggest Edit

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. Its non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure.
Ardelyx lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. 

TypePublic
Founded2007
HQFremont, US
Websiteardelyx.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2018)86(+15%)
Job Openings9
Revenue (FY, 2018)$2.6 M(-93%)
Share Price (Feb 2020)$8 (-8%)

Key People/Management at Ardelyx

Mike Raab

Mike Raab

President and Chief Executive Officer
Rac Robert Blanks

Rac Robert Blanks

Senior Vice President, Regulatory Affairs and Quality Assurance
Elizabeth Grammer

Elizabeth Grammer

Executive Vice President and General Counsel
Jeff Jacobs

Jeff Jacobs

Senior Vice President, Technical Operations
Mark Kaufmann

Mark Kaufmann

CFO
David Rosenbaum

David Rosenbaum

Chief Development Officer
Show more

Ardelyx Office Locations

Ardelyx has an office in Fremont
Fremont, US (HQ)
34175 Ardenwood Blvd
Show all (1)

Ardelyx Financials and Metrics

Ardelyx Revenue

Ardelyx's revenue was reported to be $2.61 m in FY, 2018
USD

Revenue (Q3, 2019)

3.0m

Gross profit (Q3, 2019)

2.4m

Gross profit margin (Q3, 2019), %

80.1%

Net income (Q3, 2019)

(23.5m)

EBIT (Q3, 2019)

(22.1m)

Market capitalization (21-Feb-2020)

688.2m

Closing stock price (21-Feb-2020)

8.0

Cash (30-Sept-2019)

92.7m

EV

649.6m
Ardelyx's current market capitalization is $688.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

31.6m24.0m42.0m2.6m

Revenue growth, %

Cost of goods sold

8.4m466.0k

Gross profit

33.6m2.1m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

9.1m7.6m5.9m18.1m30.0k172.0k18.0k3.0m

Cost of goods sold

464.0k2.0k600.0k

Gross profit

170.0k2.4m

Gross profit Margin, %

99%80%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

107.3m107.0m74.6m75.4m78.8m

Accounts Receivable

2.6m2.6m10.8m85.0k

Prepaid Expenses

4.9m3.2m

Inventories

1.2m5.0m3.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.2m)(29.6m)(112.4m)(64.3m)(91.3m)

Depreciation and Amortization

302.0k829.0k1.3m2.6m2.7m

Inventories

(2.3m)

Accounts Payable

831.0k(371.0k)2.1m(1.0m)(2.7m)
USDY, 2019

EV/EBIT

-29.4 x

EV/CFO

-9.9 x

Financial Leverage

2.4 x
Show all financial metrics

Ardelyx Online and Social Media Presence

Embed Graph

Ardelyx News and Updates

Global Hyperkalemia Market Report 2020; Forecast to 2022 - Featuring Profiles of Ardelyx, Astrazeneca, and Vifor Pharma

DUBLIN, Feb. 11, 2020 /PRNewswire/ -- The "Hyperkalemia Market" report has been added to ResearchAndMarkets.com's offering. This report provides exposure to the hyperkalemia market. The report also highlights current and future market potential along with a detailed analysis of the...

Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public...

Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

FREMONT, Calif., Dec. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term...

Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief...

Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that the U.S. Food and Drug...

Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September...
Show more

Ardelyx Blogs

Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference Content Import Wed, 02/19/2020 - 08:01 Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference Feb 19,2020 This release is a backfill from a News Wire …

Ardelyx Announces Proposed Public Offering of Common Stock

FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public

Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study Content Import Mon, 12/02/2019 - 16:01 Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study Dec 02,2019 T…

Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference

FREMONT, Calif. , Nov. 26, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive officer of

Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

- Companies establish a research collaboration with associated options to license any resulting development candidates with the potential for up to $500 million in development and sales milestones for Ardelyx - In addition, Kyowa Kirin makes $20 million equity investment in Ardelyx FREMONT, Calif.

Ardelyx Announces Presentation at Kidney Week 2019

Ardelyx Announces Presentation at Kidney Week 2019 Content Import Wed, 11/06/2019 - 16:07 Ardelyx Announces Presentation at Kidney Week 2019 Nov 06,2019 This release is a backfill from a News Wire General Late breaking oral presentati…
Show more

Ardelyx Frequently Asked Questions

  • When was Ardelyx founded?

    Ardelyx was founded in 2007.

  • Who are Ardelyx key executives?

    Ardelyx's key executives are Mike Raab, Rac Robert Blanks and Elizabeth Grammer.

  • How many employees does Ardelyx have?

    Ardelyx has 86 employees.

  • What is Ardelyx revenue?

    Latest Ardelyx annual revenue is $2.6 m.

  • What is Ardelyx revenue per employee?

    Latest Ardelyx revenue per employee is $30.3 k.

  • Who are Ardelyx competitors?

    Competitors of Ardelyx include Alzheon, Valneva and SciClone Pharmaceuticals.

  • Where is Ardelyx headquarters?

    Ardelyx headquarters is located at 34175 Ardenwood Blvd, Fremont.

  • Where are Ardelyx offices?

    Ardelyx has an office in Fremont.

  • How many offices does Ardelyx have?

    Ardelyx has 1 office.